Cortex’ Clinical Hold On CX717 Lifted By FDA

The company may resume clinical trials of the compound, which it has studied for Alzheimer's disease and attention deficit/hyperactivity disorder.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet